The current valuation score of Eli Lilly and Co is 8.84, ranking 69 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 42.05, which is 223.64% below the recent high of 136.10 and 21.19% above the recent low of 33.14.
P/E
Relevant data have not been disclosed by the company yet.
P/B
Relevant data have not been disclosed by the company yet.
P/S
Relevant data have not been disclosed by the company yet.
P/CF
Relevant data have not been disclosed by the company yet.